AZN.L vs. ^GSPC

In the year-to-date period, AZN.L achieves a 1.81% return, which is significantly higher than ^GSPC's -4.26% return. Over the past 10 years, AZN.L has outperformed ^GSPC with an annualized return of 12.22%, while ^GSPC has yielded a comparatively lower 10.31% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for AstraZeneca plc (AZN.L) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AZN.L Sharpe Ratio is -0.52, which is lower than the ^GSPC Sharpe Ratio of 0.51. The chart below compares the historical Sharpe Ratios of AZN.L and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

The maximum AZN.L drawdown since its inception was -49.99%, smaller than the maximum ^GSPC drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for AZN.L and ^GSPC. For additional features, visit the drawdowns tool.

AstraZeneca plc (AZN.L) and S&P 500 (^GSPC) have volatilities of 10.88% and 11.43%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.